Mir-29c Expression in Glioma and Its Effects on Tumor Cell Proliferation and Apoptosis.
Apoptosis
Cell proliferation
Expression level
Glioma
MicroRNAs
Journal
Iranian journal of public health
ISSN: 2251-6085
Titre abrégé: Iran J Public Health
Pays: Iran
ID NLM: 7505531
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
entrez:
29
5
2020
pubmed:
29
5
2020
medline:
29
5
2020
Statut:
ppublish
Résumé
To investigate the expression of microRNA-29c (miR-29c) in glioma and its effects on cell proliferation and apoptosis. A retrospective analysis was performed on 76 glioma patients in People's Hospital of Weifang, Weifang, Shandong, China from May 2013 to June 2017 (experimental group) and 63 healthy subjects in the same period (control group). qRT-PCR was used to detect the miR-29c expression. Changes of serum miR-29c expression level and the correlation of miR-29c of glioma patients with the degree of tumor differentiation and pathological type were observed. Cells were grouped before transfection into blank group (no transfection), negative control group (transfected with miRNA NC) and experimental group (transfected with miR-29c mimics). CCK-8 assay was used to detect cell proliferation, flow cytometry to detect apoptosis. Expression of miR-29c in serum was significantly lower in experimental group than that in control group ( miR-29c could inhibit the proliferation of glioma cells and promote apoptosis. miR-29c is lowly expressed in glioma, and the overexpression of which in glioma cells can inhibit tumor cells proliferation and promote apoptosis. It may be a tumor suppressor miRNA of glioma, and the expression level of which can be used as reference for evaluating the grade of glioma. It is indicated that the abnormal expression of miR-29c may be a key factor in the occurrence and development of glioma.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate the expression of microRNA-29c (miR-29c) in glioma and its effects on cell proliferation and apoptosis.
METHODS
METHODS
A retrospective analysis was performed on 76 glioma patients in People's Hospital of Weifang, Weifang, Shandong, China from May 2013 to June 2017 (experimental group) and 63 healthy subjects in the same period (control group). qRT-PCR was used to detect the miR-29c expression. Changes of serum miR-29c expression level and the correlation of miR-29c of glioma patients with the degree of tumor differentiation and pathological type were observed. Cells were grouped before transfection into blank group (no transfection), negative control group (transfected with miRNA NC) and experimental group (transfected with miR-29c mimics). CCK-8 assay was used to detect cell proliferation, flow cytometry to detect apoptosis.
RESULTS
RESULTS
Expression of miR-29c in serum was significantly lower in experimental group than that in control group (
CONCLUSION
CONCLUSIONS
miR-29c could inhibit the proliferation of glioma cells and promote apoptosis. miR-29c is lowly expressed in glioma, and the overexpression of which in glioma cells can inhibit tumor cells proliferation and promote apoptosis. It may be a tumor suppressor miRNA of glioma, and the expression level of which can be used as reference for evaluating the grade of glioma. It is indicated that the abnormal expression of miR-29c may be a key factor in the occurrence and development of glioma.
Types de publication
Journal Article
Langues
eng
Pagination
304-311Informations de copyright
Copyright © Iranian Public Health Association & Tehran University of Medical Sciences.
Déclaration de conflit d'intérêts
Conflicts of interests The authors declare that there is no conflict of interests.
Références
Oncotarget. 2016 Dec 27;7(52):85905-85916
pubmed: 27829234
J Neurooncol. 2014 May;118(1):39-47
pubmed: 24595468
J Neurooncol. 2013 Nov;115(2):179-88
pubmed: 23943502
Int J Clin Exp Med. 2015 Dec 15;8(12):22227-36
pubmed: 26885198
Acta Neurochir (Wien). 2015 Dec;157(12):2199-200
pubmed: 26385112
Oncotarget. 2016 Aug 2;7(31):50229-50238
pubmed: 27384876
CNS Neurosci Ther. 2015 Jan;21(1):40-51
pubmed: 25230316
EMBO Rep. 2009 Apr;10(4):400-5
pubmed: 19247375
Surg Neurol Int. 2015 Feb 13;6(Suppl 1):S9-S44
pubmed: 25722939
Physiol Genomics. 2012 Feb 27;44(4):237-44
pubmed: 22214600
Int J Mol Med. 2018 Jan;41(1):284-292
pubmed: 29115407
Cancer Res. 2016 Apr 15;76(8):2432-42
pubmed: 26921329
Chin Med J (Engl). 2000 Jul;113(7):662-6
pubmed: 11776043
Br J Cancer. 2017 Sep 26;117(7):1036-1047
pubmed: 28787434
Oncotarget. 2017 Jun 22;8(37):61510-61527
pubmed: 28977881
Curr Pharm Des. 2016;22(8):1033-48
pubmed: 26654773
Genes Dev. 2007 Nov 1;21(21):2683-710
pubmed: 17974913
J Physiol Biochem. 2016 Jun;72(2):201-11
pubmed: 26893028
Cold Spring Harb Protoc. 2010 Jun;2010(6):pdb.prot5439
pubmed: 20516177
Cancer Lett. 2013 Feb 28;329(2):181-8
pubmed: 23142282
Neuroreport. 2013 Aug 21;24(12):637-45
pubmed: 23744344
BMC Cancer. 2016 Mar 15;16:218
pubmed: 26975503
Cytometry. 1993 Nov;14(8):891-7
pubmed: 8287732
Ann Oncol. 2015 Oct;26(10):2199-200
pubmed: 26187445
Mol Cancer Ther. 2017 Dec;16(12):2840-2848
pubmed: 28802251
Methods Mol Biol. 2011;676:211-23
pubmed: 20931400